Abstract:Anthracycline-induced cardiotoxicity (ACT) is a well-known serious adverse drug reaction leading to substantial morbidity. The purpose of this study was to assess ACT occurrence and clinical and genetic risk factors in early breast cancer patients. In 6 genes of interest (ABCC1, ABCC2, CYBA, NCF4, RAC2, SLC28A3), 10 single nucleotide polymorphisms (SNPs) involved in ACT were selected based on a literature search. Eight hundred and seventy-seven patients treated between 2000 and 2010 with 3-6 cycles of (neo) adjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC) were genotyped for these SNPs using Sequenom MassARRAY. Main outcome measures were asymptomatic decrease of left ventricular ejection fraction (LVEF) > 10 % and cardiac failure grade 3-5 (CTCAE 4.0). To evaluate the impact of these 10 SNPs as well as clinical factors (age, relative dose intensity of epirubicin, left-sided radiotherapy, occurrence of febrile neutropenia, and planned and received cycles of epirubicin) on decrease of LVEF and cardiac failure, we performed uni- and multivariable logistic regression analysis. Additionally, exploratory analyses including 11 additional SNPs related to the metabolism of anthracyclines were performed. After a median follow-up of 3.62 years (range 0.40-9.60), a LVEF decline of > 10 % occurred in 153 patients (17.5 %) and cardiac failure in 16 patients (1.8 %). In multivariable analysis, six cycles of FEC compared to three cycles received and heterozygous carriers of the rs246221 T-allele in ABCC1 relative to homozygous carriers of the T-allele were significantly associated with LVEF decline of > 10 % (OR 1.3, 95 % CI 1.1-1.4, p < 0.001 and OR 1.6, 95 % CI 1.1-2.3, p = 0.02). Radiotherapy for left-sided breast cancer was associated with cardiac failure (OR 3.7, 95 % CI 1.2-11.5, p 0.026). The other 9 SNPs and clinical factors tested were not significantly associated. In our exploratory analysis, no other SNPs related to anthracycline metabolism were retained in the multivariate model for prediction of LVEF decline. ACT in breast cancer patients is related to number of received cycles of epirubicin and left-sided radiotherapy. Additional studies should be performed to independently confirm the potential association between rs246221 in ABCC1 and LVEF.

Genetics of Anthracycline-Associated Cardiotoxicity

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity

Genetic factors in the pathogenesis of cardio-oncology

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis

Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis

Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment

Genetic Variants Associated with Therapy-Related Cardiomyopathy among Childhood Cancer Survivors of African Ancestry

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer

The Cardiotoxicology of Anthracycline Chemotherapeutics

Anthracycline Chemotherapy and Cardiotoxicity

Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective

Hypertension Susceptibility Loci Are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Research progress in pathogenesis,diagnosis and treatment of anthracyclines related cardiotoxicity

Anthracycline-induced cardiotoxicity: From pathobiology to identification of molecular targets for nuclear imaging